nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.12.2019 | editorial

Amazing advances in the field of uro-oncology

verfasst von: Dora Niedersüß-Beke

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Excerpt

After many years of stagnation, especially in bladder cancer, a new era has started with the approval of the checkpoint inhibitors in bladder cancer and renal cell carcinoma. …

Vorheriger Artikel An update from the 2019 ASCO Annual Meeting

Nächster Artikel Optimizing care for geriatric cancer patients: the greatest challenge in medical oncology?

Madersbacher S. Management of nonmetastatic muscle invasive bladder cancer in the elderly. memo. 2019. https://doi.org/10.1007/s12254-019-00547-2.CrossRef

Brönimann S, Shariat SF, Hassler MR. Nonmuscle invasive urothelial cancer—Bacillus Calmette-Guérin instillation or checkpoint inhibitor immunotherapy? Memo. 2019. https://doi.org/10.1007/s12254-019-00527-6.CrossRef

Hutterer GC, Pichler M. Advanced/metastatic urothelial carcinoma of the bladder and upper urinary tract. Memo. 2019. https://doi.org/10.1007/s12254-019-00532-9.CrossRef

Brönimann S, D’Andrea D, Shariat SF, Gust KM. Neoadjuvant therapy in urothelial cancer—new therapies on the horizon. Memo. 2019. https://doi.org/10.1007/s12254-019-00533-8.CrossRef

Marszalek M. First-line treatment of metastatic renal cell carcinoma: current standard of care. memo. 2019. https://doi.org/10.1007/s12254-019-00550-7.CrossRef

Vogl U. Second-line therapy in metastatic renal cell cancer—how do we treat after immuno-oncology drugs? memo. 2019. https://doi.org/10.1007/s12254-019-00545-4.CrossRef

Terzic J, Bauernhofer T. Biomarkers in renal cell carinoma. Memo. 2019. https://doi.org/10.1007/s12254-019-00549-0.CrossRef

Lenart S, Berger I, Hartig N, Madersbacher S, Ponholzer A. Surgery in renal cell carcinoma—when, whom and how? Memo. 2019. https://doi.org/10.1007/s12254-019-00548-1.CrossRef

Titel: Amazing advances in the field of uro-oncology
verfasst von: Dora Niedersüß-Beke
Publikationsdatum: 01.12.2019
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-019-00536-5

Biomarkers in renal cell carcinoma

short review

Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria

Open Access
original report

ASCO 2019: highlights in HER2-positive metastatic breast cancer

Open Access
review

HPV-associated cancers

Open Access
short review

First-line treatment of metastatic renal cell carcinoma: current standard of care

short review

Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?

Open Access
short review

Springer Medizin Österreich

Amazing advances in the field of uro-oncology

Excerpt

Weitere Artikel der Ausgabe 4/2019

Biomarkers in renal cell carcinoma

Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria

ASCO 2019: highlights in HER2-positive metastatic breast cancer

HPV-associated cancers

First-line treatment of metastatic renal cell carcinoma: current standard of care

Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Biomarkers in renal cell carcinoma

Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria

ASCO 2019: highlights in HER2-positive metastatic breast cancer

HPV-associated cancers

First-line treatment of metastatic renal cell carcinoma: current standard of care

Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?